INTRODUCTION
In patients with cirrhosis and portal hypertension the goal of therapy is to reduce portal pressure without deteriorating hepatic perfusion [1] . While hepatic venous pressure gradient (HVPG) measurement is a consistent and reproducible surrogate of portal pressure in cirrhosis [2] , there is an unmet need for reliable techniques to assess total hepatic blood flow (HBF) in clinical practice.
The indocyanine green (ICG) constant infusion technique [3] has been widely used to estimate HBF by Fick's method in healthy subjects [4] and in patients with cirrhosis [5, 6] . This method is objective and reproducible, and is currently considered the gold standard for HBF quantitative measurement. However, this technique requires hepatic vein catheterization, and cannot be used routinely.
Given the limitations of ICG-based HBF measurement (ICG-HBF), non-invasive methods to estimate HBF have been investigated. Doppler duplex ultrasonography
(DUS) allows a non-invasive study of abdominal organs and abdominal circulation in real time, and has been widely used to assess the circulatory abnormalities occurring in patients with cirrhosis and portal hypertension [7, 8] . DUS allows evaluating separately the two components of total HBF, namely portal vein blood flow (PBF) and hepatic artery blood flow (HABF) [9] , but while DUS has been proved reliable for PBF estimation [10] , very limited and inconclusive data exist on DUS-based measurement of total HBF in patients with cirrhosis [11] .
The aim of this study was to assess the consistency and agreement of Doppler ultrasound for the assessment of hepatic blood flow in patients with cirrhosis by comparing this method with HBF estimated by the gold standard (HBF by ICG by Fick's method during hepatic vein catheterization).
METHODS
This study was approved by the Ethics Committee of Hospital Clinic. The nature of the study was explained to the patients, and a written informed consent was obtained in each case, according to the principles of the Declaration of Helsinki (revision of Edinburgh 2000).
Patients
50 patients with liver cirrhosis and hepatopetal portal blood flow, with valid measurements of ICG-HBF and valid measurements of both PBF and HABF by DUS, admitted to our Laboratory for hepatic venous pressure gradient measurement, were included in this study. Exclusion criteria were the following: age <18 or >80 years; pregnancy; hepatocellular carcinoma; portal vein thrombosis; extraction index of ICG < 0.1 [5] ; insufficient visualization of the portal vein and hepatic artery. This last criterion led to the exclusion of 9 patients. Tab. 1 shows the main clinical and laboratory characteristics of the studied population.
Hepatic venous pressure gradient and HBF by Indocyanine green (ICG-HBF) measurement
Patients underwent hepatic vein catheterisation in the morning after at least 8 hour fasting. Under local anaesthesia, with ultrasonographic guidance (SonoSite Inc, Bothell, WA) a 8F venous catheter introducer (Axcess; Maxxim Medical, Athens, TX, USA) was placed in the right internal jugular vein using the Seldinger technique. Thereafter, a 7F balloon-tipped catheter (Edwards Lifesciences, Irvine, CA, USA) was advanced into the right hepatic vein to measure wedged and free hepatic venous pressures (WHVP and FHVP, respectively) by the connection to external electro-mechanical transducer and polygraph (Mac-Lab®, GE Healthcare, Freiburg, Germany). HVPG was calculated as WHVP -FHVP [2] .
Preceded by a priming dose of 5 mg, a solution of indocyanine green (Pulsion Medical Systems, Munich, Germany) was infused intravenously at a constant rate of 0.2 mg/min.
After an equilibration period of at least 40 minutes to achieve a steady-state, 4 separate sets of simultaneous samples of peripheral and hepatic venous blood were obtained for the measurement of hepatic blood flow according to the Fick's method as previously described [12] . To avoid interferences from differences in plasma turbidity, the Nielsen's correction was used [5] at the moment of reading ICG concentration in the samples by spectrophotometry (SP-830, Turner Biosystems, Sunnyvale, CA, USA). 
HBF by Doppler Ultrasound (US-HBF)
Patients underwent DUS examination on the same morning of hepatic vein catheterization, after an overnight fast, before undergoing the invasive procedure. They were invited to lie supine for 10 minutes. Thereafter, Doppler measurements were performed using a Siemens ACUSON Sequoia™ 512 (Acuson, Mountain View, CA, USA) ultrasound system, by the same physician in order to avoid interobserver variability. A 3.5-5 MHz convex probe provided by a color, power and pulsed Doppler software was used. Following current recommendations [7, 8] , portal vein and hepatic artery were imaged by B-mode. The gain was reduced and the image size made as large as possible to improve resolution. Diameter and flow velocity were measured in both vessels during short time suspended normal respiration using an oblique scan in the epigastrium in a standardized site (crossing of hepatic artery and portal vein). Insonation angles of 50-55º were used for these measurements. The Doppler sample was positioned in the center of the lumen, setting its dimension as wide as ≥ 50% of the vessel diameter.
Measurements were taken in triplicate, and the results were expressed as the mean value. Variability between different measures was <10%. Intraobserver variability was previously assessed and was < 10%.
Time averaged maximum velocity in the portal vein and in the hepatic artery was obtained from delineation of the Doppler spectral signal. Portal blood velocity was calculated as time averaged maximum velocity multiplied by 0.57, assuming the portal velocity profile as parabolic, as previously reported [13, 14] . Similarly, hepatic artery velocity was calculated as time averaged maximum velocity multiplied by 0.62, as previously reported [7, 8] .
Portal blood flow (PBF) and hepatic artery blood flow (HABF) were obtained by multiplying the portal vein cross-sectional area, assuming a circular shape of the portal vein and hepatic artery section, by the mean velocity of blood flow in the vessel [10, 13, 14] according to the following formula:
Blood flow (ml/min) = cross sectional area of the vessel* mean flow velocity (cm/s)*60
Total hepatic blood flow (US-HBF) was then calculated as PBF + HABF.
The percentage of US-HBF provided by PBF and HABF was calculated as: PBF/US-HBF*100 and HABF/US-HBF*100.
Congestion index of the portal vein was calculated as previously reported by Moriyasu et al. [15] as follows:
Congestion Index= cross-sectional area of the portal vein (cm 2 )/ portal vein mean flow velocity (cm/s). We arbitrarily defined as "clinically important difference" a difference between US-HBF and ICG-HBF 20%. Receiver operating characteristics curve (ROC) analysis was used to identify the most specific cut-off of the tested parameters able to detect this clinically important difference in HBF as compared with ICG-HBF.
Statistical analysis

Means of ICG-HBF and US-HBF were compared by paired T-test or
The α value was set at 0.05. All p-values are two-sided. Statistical analysis was performed with SPSS 16.0 package (SPSS, Chicago, IL, USA). Table 2 shows the results of DUS examination, US-HBF and ICG-HBF in the 50 patients included, and Table 3 is accurate and reproducible [9, 17] , and age, sex, height, weight and body surface area do not modify the accuracy of measurements of PBF by DUS in human subjects [18] .
RESULTS
On the other hand it is well known that Doppler measurements in vivo exhibit a large variability which can be due to anatomical (limitations of the angle between the Doppler beam and the vessel), physiologic phenomena (e.g. meal ingestion) and to intra-and inter-observer errors [19, 20] . While anatomical features cannot be modified, variability due to the remaining factors can be minimized by applying standardized protocols of examination as suggested by EFSUMB recommendations [8] , which were carefully adhered to in the present study.
Despite using a careful, standardized protocol for DUS examination [8] we observed that the discrepancy between US-HBF (and PBF) by DUS and ICG-HBF increased as the value of HBF by any of the two methods increased. This data is in agreement with the results obtained by Bolognesi et al. in 27 patients with cirrhosis regarding the agreement of PBF by DUS and ICG-HBF [11] . In contrast, we could not reproduce the existence of a strong correlation between PBF by DUS and ICG-HBF in the whole population we included. This probably depends upon differences in the proportion of patients with compensated and decompensated cirrhosis included in the two studies, since at a closer look of our data US-HBF and PBF by DUS were well correlated with ICG-HBF in patients with well compensated cirrhosis, who were the majority in the study by Bolognesi et al [11] . Another major difference with the study by Bolognesi et al. [11] regards the availability of data on HABF in our study.
Our data suggest that while HABF is minimally relevant in terms of correlation with ICG-HBF in patients with compensated cirrhosis and preserved liver function, its careful estimation is very important in patients with decompensated cirrhosis and advanced liver failure, since in this subset no correlation between PBF by DUS and ICG-HBF exists. This supports that hepatic blood flow is largely influenced by HABF rather than by PBF in decompensated patients, who very frequently have extensive portal-systemic collaterals. This is well in accordance with the fact that, as demonstrated by our study, the more arterialized the liver is, the less reliable is the measurement of HBF by Doppler, as compared to the gold-standard technique.
Some limitations of our work should be acknowledged. The first is due to the fact that HBF estimation by ICG technique is an imperfect gold-standard. The rational for using this method is the fact that ICG is primarily non-reversibly extracted by the liver (about 70%) [21] , being HBF the main determinant of its clearance. Nonetheless, it has been previously shown that errors in the estimation of HBF by ICG arise when the hepatic extraction of the compound is <10%, as it may occur in patients with severe hepatic failure. In this paper we excluded this population, and restricted the analysis to patients with ICG extraction >0.1; still, two patients with ICG extraction index below 0.2 had very high, unlikely values of ICG-HBF, suggesting an estimation error by this technique. New methods of liver perfusion estimation, such as the application of mathematical models (e.g. dual-inlet two-compartment uptake model) to dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) using a specific hepatobiliary contrast agent (gadoxetic acid) [22] , or positron emission tomography (PET) using oxygen-15 labeled water [23] , might represent better gold-standards for future studies, although may be inconvenient for its use in clinical practice.
Another limitation is due to our inclusion criteria, which limited the study to patients in whom both PBF and HABF could be measured. It was previously reported that hepatic artery visualization is possible only in a minority of patients with cirrhosis [9, 11] ; this was not the case in our series, since both the portal vein and the hepatic artery could be assessed in 85% of cases. Advances in the technology applied to ultrasound equipments might explain this discrepancy.
Since only one physician performed all the measurements, interobserver variability was not assessed in the present study. However, as previously stated, we applied standardized, well accepted protocols of examination [8] which have been previously
shown to reduce interobserver variability [19, 20] .
Finally, in order to give a pragmatic applicability of our findings, we examined which factor may allow excluding patients with an excessive risk of unreliable results on the basis of Doppler measurements of total hepatic blood flow, that we arbitrarily set as difference of >20% ("clinically relevant difference"). In that regard, it is important to remark our finding that patients with excessive liver arterialization (i.e., a hepatic artery fraction of total liver blood flow > 40%) had a 90% chance of exhibiting such a clinically significant discrepancy and therefore, US-HBF should be considered unreliable in such patients. Even if we believe that this finding is reasonably robust, we acknowledge that it can be questioned until confirmed by independent studies.
In conclusion, our data provide new evidence regarding the use of Doppler-US as a noninvasive method to estimate hepatic blood flow. Future studies using the combination of Doppler-US and elastographic methods [24] [25] [26] for non-invasive assessment of changes in intrahepatic haemodynamics (a new target for the treatment of portal hypertension [27] ) should take into account the limitations of Doppler-US.
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